

**Amendments to the Claims**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

Claim 1 (currently amended): A crystal of an androgen receptor ligand binding domain (AR-LBD) consisting of amino acids 13 through 258 of SEQ ID NO:1 complexed with an AR-LBD ligand that is dihydroxytestosterone, said crystal belonging to the space group P212121 and having the unit cell dimensions  $a = 56.03$  angstrom,  $b = 66.27$  angstrom, and  $c = 70.38$  angstrom.

Claims 2-10 (canceled)

Claim 11 (previously presented): The crystal of claim 1 that has an AR-LBD ligand binding site defined by the structure coordinates of AR-LBD amino acids V685, L700, L701, S702, S703, L704, N705, E706, L707, G708, E709, Q711, A735, I737, Q738, Y739, S740, W741, M742, G743, L744, M745, V746, F747, A748, M749, G750, R752, Y763, F764, A765, L768, F770, M780, M787, I869, L873, H874, F876, T877 and F878 according to Table A.

Claim 12 (canceled)

Claim 13 (previously presented): The crystal of claim 1 that has an AR-LBD ligand binding site defined by the structure coordinates of AR-LBD amino acids N705, Q711, R752, F764 and T877 according to Table A.

Claims 14-33 (canceled)